Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.51 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.51 |
| ▸ | HTR1D | P28221 | 3/20 | 0.51 |
| ▸ | HTR1B | P28222 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18412741 | 0.87 | IMPDH2 (0.51) | IMPDH2IMPDH1HTR1DHTR1BSLC6A4 | |
| SCHEMBL6599646 | 0.77 | IMPDH2 (0.56) | IMPDH2IMPDH1HTR1DSLC6A4SLC6A2 | |
| SCHEMBL27831763 | 0.76 | IMPDH2 (0.44) | IMPDH2IMPDH1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL14827779 | 0.75 | HTR1D (0.57) | HTR1DHTR1BHTR2ACDK9 | |
| SCHEMBL15912345 | 0.75 | HTR1D (0.57) | HTR1DHTR1BHTR2A | |
| SCHEMBL12376509 | 0.74 | HTR1D (0.55) | HTR1DHTR1BHTR2A | |
| SCHEMBL22479037 | 0.74 | HTR1D (0.55) | HTR1DHTR1BHTR2AHASPIN | |
| SCHEMBL2006656 | 0.74 | IMPDH2 (0.56) | IMPDH2IMPDH1HTR1DHTR1BSLC6A4 | |
| SCHEMBL12427125 | 0.74 | IMPDH2 (0.56) | IMPDH2IMPDH1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL186728 | 0.74 | CSNK2A1 (0.58) | IMPDH2IMPDH1SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169654-A1 | New Organic Compounds | SERVIER PHARMACEUTICALS LLC (US) | 2022-06-02 | — | — | US | disclosed |
| US-20210355112-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| US-11091467-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200354345-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355112-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | IMPDH2 2800/4885IMPDH1 2508/4885HTR1D 1537/4885 |
| US-20200354345-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | IMPDH2 2800/4885IMPDH1 2508/4885HTR1D 1537/4885 |
| US-20220169654-A1 | New Organic Compounds | MNAT1, MAT2A, EIF4A2 | IMPDH2 1061/4885IMPDH1 1398/4885HTR1D 213/4885 |
| US-11091467-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | IMPDH2 2881/4885IMPDH1 2599/4885HTR1D 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.